The Food and Drug Administration has approved Lembaz, or adrabetadex, for adults and children with a severe early-onset form of Niemann-Pick disease type C, making it the first treatment the agency says has been shown to reduce the risk of death in that population.
The Nov. 17 approval offers a new option for a rare inherited disorder that progressively damages the nervous system and can cause premature death. But the benefit comes with demanding treatment: Lembaz is injected into the fluid around the spinal cord every two weeks and carries a boxed warning for hearing impairment, including potentially permanent hearing loss.
Who is eligible for Lembaz
According to the FDA announcement, Lembaz is approved for patients who weigh at least 7 kilograms and whose neurological symptoms of Niemann-Pick disease type C, or NPC, began before age 6. The indication includes both pediatric and adult patients.
That wording is important because “infantile-onset” describes when neurological symptoms began, not necessarily the patient’s age when treatment starts. Some accounts of the drug’s development have described it as a treatment for infants. The approved population is broader than that description, although it does not cover every person with NPC or every age at which the disease can begin.
NPC affects an estimated one in 150,000 people, the FDA said. It is a lysosomal storage disorder: cells have difficulty processing cholesterol and other fats, which accumulate and contribute to damage in the brain and elsewhere. Symptoms can vary, but the disease is associated with worsening coordination, cognition, movement and other neurological functions.
The approval was granted to Mandos LLC, a subsidiary of Beren Therapeutics PBC. The company said in its announcement of the decision that it expected commercial availability in early December. That is a company projection rather than confirmation that the drug is already available at particular treatment centers.
What the survival evidence showed
The FDA’s review centered on survival data from 36 Lembaz-treated patients whose neurological symptoms had started before age 6. The patients came from three clinical studies and an expanded-access program. The agency compared their outcomes with those of matched external controls rather than with a concurrently randomized control group.
The agency said treated patients had a 55% lower risk of death than the matched controls. Median survival was 8.5 years for patients receiving Lembaz, compared with 4.9 years for the external-control group. The FDA also said the observed survival benefit appeared whether or not patients were taking miglustat, a drug used off-label in NPC.
For an ultra-rare disease, assembling a conventional large randomized mortality trial can be difficult. Still, an external-control analysis has limits that differ from a randomized study. Matching can account for some known differences between groups, but it cannot fully eliminate the possibility that unmeasured differences in disease severity, access to care, treatment timing or other factors affected survival.
The publicly available FDA summary does not provide the control-group size, details of the matching process, follow-up duration, baseline characteristics or statistical confidence intervals. It also combines patients treated in several studies and an expanded-access setting, which may not be identical clinical environments. The agency’s approval represents its assessment that the total evidence supported the labeled use, but the available material does not describe a randomized trial proving a mortality effect on its own.
Earlier late-stage research had a more complicated path. A Medical Xpress report on the NIH-led research history said that a multinational late-phase trial produced positive biomarker findings but did not meet the clinical outcome measures needed for approval at that time. Researchers and collaborators then evaluated survival information that helped support the eventual regulatory decision.
Hearing risk and treatment burden
Lembaz must be administered intrathecally by a trained health-care provider, meaning an injection is delivered into the spinal fluid. The approved schedule is once every two weeks, adding a recurring procedure to the care required for a complex neurological disease.
Its boxed warning calls attention to hearing impairment, including permanent hearing loss. The FDA recommends hearing testing before treatment begins and at regular intervals during treatment; dose changes may be needed. Families and clinicians weighing treatment would need to consider that safety risk alongside the potential survival benefit.
Other commonly reported adverse effects include problems with balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea and cough. Some of those symptoms may be especially difficult to distinguish clinically in a disorder that itself can affect neurological function, although the FDA announcement does not detail how often individual reactions occurred or how they compared with the external-control group.
A two-decade development effort
The approval follows years of research into cyclodextrin-based treatment for NPC. NIH researchers began a natural-history study in 2006, after earlier work helped identify the genetic basis of the disease. The program later moved through an early-phase study at the NIH Clinical Center and multinational trials supported through collaborations with academic investigators and companies.
Adrabetadex is a cyclodextrin-based therapy, but the FDA-approved product name is Lembaz. The agency said two treatments had previously been approved for NPC, though neither had demonstrated a reduction in mortality risk. Lembaz’s approval is specifically tied to the early-neurological-onset, minimum-weight population in its label, and its survival findings should not be assumed to apply to later-onset forms of the disease.
For patients meeting those criteria, the decision adds a therapy with an FDA-recognized survival benefit in a condition with few options. It also leaves practical questions for specialty centers about hearing surveillance, repeated intrathecal administration and how treatment outcomes will perform beyond the relatively small group assessed in the approval review.
